Skin disorders
23 results
Applied filters
Permethrin for scabies
27 November 2025SPS PGD template for supply of permethrin for the treatment of scabies in specified patient groups.
Malathion for scabies
27 November 2025SPS PGD template for supply of malathion for the treatment of scabies in specified patient groups.
Co-amoxiclav for human and animal bites
27 November 2025SPS PGD template for supply of co-amoxiclav for the prophylaxis of human and animal bites in specified patient groups.
Doxycycline and metronidazole for human and animal bites
27 November 2025SPS PGD templates for supply of doxycycline and metronidazole for the prophylaxis of human and animal bites in specified patient groups
The licence and supporting evidence for omalizumab biosimilar
14 November 2025We highlight evidence for licensed omalizumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Xolair).
Preparing to use omalizumab biosimilar
19 September 2025Omalizumab biosimilars are expected soon. We offer general information and implementation advice.
Preparing to use ustekinumab biosimilar
29 July 2025Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing ustekinumab biosimilar
29 July 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
29 July 2025Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
Valaciclovir for shingles
24 April 2025SPS PGD template for supply of valaciclovir for shingles in specified patient groups.